Spironolactone for nonresolving central serous chorioretinopathy a randomized controlled crossover study

Retina

Volumn 35, Issue 12, 2015, Pages 2505-2515

  Bousquet, Elodie ^a,b   Beydoun, Talal ^a   Rothschild, Pierre Raphaël ^a,b   Bergin, Ciara ^c   Zhao, Min ^b   Batista, Rui ^a   Brandely, Marie Laure ^a   Couraud, Benedicte ^a   Farman, Nicolette ^d   Gaudric, Alain ^e   Chast, François ^a   Behar Cohen, Francine ^b,c  

^a HÔTEL DIEU   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d INSERM   (France)

^e HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Central serous chorioretinopathy; Choroidal thickness; Choroidal vessels; Mineralocorticoid receptor; Spironolactone; Treatment

Indexed keywords

PLACEBO; SPIRONOLACTONE; MINERALOCORTICOID ANTAGONIST;

ADULT; ARTICLE; CENTRAL SEROUS RETINOPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETINAL THICKNESS; SUBFOVEAL CHOROIDAL THICKNESS; SUBRETINAL FLUID; TREATMENT DURATION; VISUAL ACUITY; AGED; CENTRAL SEROUS CHORIORETINOPATHY; METABOLISM; MIDDLE AGED; PATHOLOGY; YOUNG ADULT;

ADULT; AGED; CENTRAL SEROUS CHORIORETINOPATHY; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PROSPECTIVE STUDIES; SPIRONOLACTONE; SUBRETINAL FLUID; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY; YOUNG ADULT;

EID: 84948466936     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000614     Document Type: Article

References (30)

1. Kitzmann AS, Pulido JS, Diehl NN, et al. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002. Ophthalmology 2008;115:169-173.
2. Wang M, Munch IC, Hasler PW, et al. Central serous chorioretinopathy. Acta Ophthalmol 2008;86:126-145.
3. Liew G, Quin G, Gillies M, Fraser-Bell S. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Experiment Ophthalmol 2013;141:201-214.
4. Spaide RF, Campeas L, Haas A, et al. Central serous chorioretinopathy in younger and older adults. Ophthalmology 1996; 103:2070-2079.
5. Brown JS, Flitcroft DI, Ying G, et al. In vivo human choroidal thickness measurements: evidence for diurnal fluctuations. Invest Ophthalmol Vis Sci 2009;50:5-12.
6. Warrow DJ, Hoang QV, Freund KB. Pachychoroid pigment epitheliopathy. Retina 2013;33:1659-1672.
7. Kim YT, Kang SW, Bai KH. Choroidal thickness in both eyes of patients with unilaterally active central serous chorioretinopathy. Eye (Lond) 2011;25:1635-1640.
8. Spaide RF, Hall L, Haas A, et al. Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina 1996;16:203-213.
9. Iida T, Kishi S, Hagimura N, Shimizu K. Persistent and bilateral choroidal vascular abnormalities in central serous chorioretinopathy. Retina 1999;19:508-512.
10. Bouzas EA, Karadimas P, Pournaras CJ. Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol 2002;47: 431-448.
11. Haimovici R, Koh S, Gagnon DR, et al. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology 2004;111:244-249.
12. Tittl MK, Spaide RF, Wong D, et al. Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol 1999;128:63-68.
13. Zhao M, Valamanesh F, Celerier I, et al. The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion and water channels in Müller glial cells. FASEB J 2010;24:3405-3415.
14. Zhao M, Célérier I, Bousquet E, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest 2012;122:2672-2679.
15. Delyani JA. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int 2000;57:1408-1411.
16. De Gasparo M, Joss U, Ramjoué HP, et al. Three new epoxyspirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987;240:650-656.
17. Bousquet E, Beydoun T, Zhao M, et al. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina 2013;33:2096-2102.
18. Guyonnet J, Elliott J, Kaltsatos V. A preclinical pharmacokinetic and pharmacodynamic approach to determine a dose of spironolactone for treatment of congestive heart failure in dog. J Vet Pharmacol Ther 2010;33:260-267.
19. Krause W, Karras J, Seifert W. Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-K in healthy man. Eur J Clin Pharmacol 1983;25:449-453.
20. Tan CSH, Li KZ, Lim TH. A novel technique of adjusting segmentation boundary layers to achieve comparability of retinal thickness and volumes between spectral domain and time domain optical coherence tomography. Invest Ophthalmol Vis Sci 2012;53:5515-5519.
21. Margolis R, Spaide RF. A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes. Am J Ophthalmol 2009;147:811-815.
22. Senn S. Cross-over trials in clinical research. Statistics in practice. 2nd Edition. Wiley 2002 pg 1-140.
23. R Core Team. A Language and Environment for Statistical Computing. Vienna, Austria: Foundation for Statistical Computing; 2012; ISBN 3-900051-07-0. Available at: http://www. R-project. org/. Accessed January 6, 2014.
24. Forooghian F, Meleth AD, Cukras C, et al. Finasteride for chronic central serous chorioretinopathy. Retina 2011;31: 766-771.
25. Rahbani-Nobar MB, Javadzadeh A, Ghojazadeh L, et al. The effect of Helicobacter pylori treatment on remission of idiopathic central serous chorioretinopathy. Mol Vis 2011;17: 99-103.
26. Nielsen JS, Jampol LM. Oral mifepristone for chronic central serous chorioretinopathy. Retina 2011;31:1928-1936.
27. Gardiner P, Schrode K, Quinlan D, et al. Spironolactone metabolism: steady-state serum levels of the sulfurcontaining metabolites. J Clin Pharmacol 1989;29: 342-347.
28. McGraw AP, McCurley A, Preston IR, Jaffe IZ. Mineralocorticoid receptors in vascular disease: connecting molecular pathways to clinical implications. Curr Atheroscler Rep 2013; 15:340.
29. Vardeny O, Cavallari LH, Claggett B, et al. Race influences the safety and efficacy of spironolactone in severe heart failure. Circ Heart Fail 2013;6:970-976.
30. Michaelis M, Hofmann PJ, Götz F, et al. Sex-specific effects of spironolactone on blood pressure in gonadectomized male and female Wistar rats. Horm Metab Res 2012;44: 291-295.